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subjective parameters reveal any signiﬁcant differences
between the groups. Side effects (numbness, headache)
were documented by two subjects receiving hay bath.
Conclusion: When using the hay bath, potential side
effects must be taken into account. In view of the
increasing use of Graminis ﬂos in phytobalneotherapy,
investigations involving large groups of patients with
deﬁned illnesses are needed in order deﬁnitively to
establish the effectiveness and risks of the hay bath.
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Phytotherapy is one of the major ﬁelds in ‘‘Klassischer
Naturheilkunde’’ in Germany and it is the most
frequented one. In 2003 more than 2 billion dollar was
spent for over-the-counter herbal treatment.
In Germany more than 300,000 patients suffer from
IBD, mainly Crohn’s disease and ulcerative colitis.
In IBD every other patient has personal experience with
CAM. Almost 44% of these patients had experience in the
ﬁeld of Herbal therapy, mainly as an adjunct to conventional
therapy in an integrated medical treatment approach.
One way to implement herbs in the treatment is self-help
strategies such as tea. Moreover, there are various herbal
preparations with promising results in the treatment of IBD.
In Germany there is major interest in the herbs isphagula,
frankinsence, myrrh and camomile for the treatment of IBD.
Moreover, ginger, curcumin, tormentill, wormworth and
green tea have shown ﬁrst promising results.
The different herbs will be introduced and existing
data or ongoing research will be presented.
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The design of a scientiﬁc study should be appropriate to
answer the study question but independent of the theorywhich generated the study question. Different study designs
will be needed to answer questions related to diagnosis,
therapy or prevention but may not be needed to investigate
different treatments founded by different theories.
Aim: Using the example of treatment-related questions
we discuss the applicability of 12 questions [Usability of
Scientiﬁc Publications (USP) Questionnaire; manuscript
submitted] to studies of complementary alternative
medicine.
Methods: Q1 Was the aim of the study clearly stated?
Q2 Was the design appropriate to answer study question?
Q3 Can the design of the study be used in a conﬁrmatory
study? Q4 Were the risk proﬁles of the study populations
similar? Q5 Was the allocation of patients to study
groups concealed? Q6 Were doctors and patients
continuously blinded? Q7 Was the follow up long enough
to detect the deﬁned endpoint? Q8 Were all patients
included in reported results? Q9 Were adequate statistics
applied? Q10 Were the results inﬂuenced by conﬂicting
interests? Q11 Is the validity of report acceptable? Q12 Is
the described effect clinically relevant?
Result: The questions Q1, Q2, Q7–Q10 and Q12 can be
answered without speciﬁc instruction. Possible answers
to the other questions are: Q3 The designs of some
studies are ambiguous and not clear enough to be used in
a conﬁrmatory study. Q4 The risks of harm may be
imbalanced among the investigated groups. Imbalanced
means that most of the risk factors indicate a marginally
higher risk of harm in one of the investigated groups. Q5
The answer to this question is ‘‘no’’ if the allocation to a
particular treatment group can be predicted. Q6 In some
studies doctors and/or patients can identify rather fast to
which treatment a particular patient is allocated. Q11
This question should be answered by a group of
advocates and skeptics of the tested treatment.
Conclusion: It is not possible to recommend a ‘‘one ﬁts
all’’ study design but the criteria can be speciﬁed which
inﬂuence the validity of the study results. Two interesting
aspects have to be discussed in more detail, the role of
randomization and the threshold of validity. Increasing
evidence indicates that both aspects may be more a
societal than a scientiﬁc problem.
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